Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F24%3A10485855" target="_blank" >RIV/00216208:11110/24:10485855 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=C2X_NmI2K5" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=C2X_NmI2K5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00384-024-04727-3" target="_blank" >10.1007/s00384-024-04727-3</a>
Alternative languages
Result language
angličtina
Original language name
Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab
Original language description
Purpose: Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective. Methods: In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index >= 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn's disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12. Results: Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months 6 and 12, respectively. No immediate hypersensitivity reactions were observed. Two patients discontinued IFX SC treatment because of delayed hypersensitivity at week 2 and week 4. IFX serum concentrations increased from baseline to month 12, while anti-drug antibody levels decreased. Combined clinical and biochemical remission at month 12 was observed in seven of 20 patients (35%). Conclusion: Subcutaneous infliximab treatment of Crohn's disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn's disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International Journal of Colorectal Disease
ISSN
0179-1958
e-ISSN
1432-1262
Volume of the periodical
39
Issue of the periodical within the volume
1
Country of publishing house
DE - GERMANY
Number of pages
8
Pages from-to
151
UT code for WoS article
001319793400001
EID of the result in the Scopus database
2-s2.0-85204900025